-
Product Insights
Net Present Value Model: Rocket Pharmaceuticals Inc’s Ladilen
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's Ladilen report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iparomlimab + Tuvonralimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iparomlimab + Tuvonralimab in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iparomlimab + Tuvonralimab in Metastatic Colorectal Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iparomlimab + Tuvonralimab in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iparomlimab + Tuvonralimab in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iparomlimab + Tuvonralimab in Cervical CancerDrug Details:Tuvonralimab (PSB-205) in combination with iparomlimab is under...
-
Company Insights
Innovation and Patenting activity of Cogent Biosciences Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cogent Biosciences Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Cogent Biosciences Inc – Company Profile
Cogent Biosciences Inc (Cogent Biosciences), formerly Unum Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops and commercializes precision therapies for genetically defined diseases. The company's pipeline product portfolio includes CGT9486 which is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Cogent Biosciences's KIT D816V is responsible for driving systemic mastocytosis a serious disease caused by the unchecked proliferation of mast cells. It carries out clinical...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastrointestinal stromal tumors (GIST) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. Its treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy. The Gastrointestinal Stromal Tumor pipeline market research report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Net Present Value Model: Bezuclastinib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Bezuclastinib Drug Details CGT-9486 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Bezuclastinib Drug Details CGT-9486 is under development for gastrointestinal stromal tumor, advanced systemic mastocytosis...
-
Product Insights
Systemic Mastocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Systemic Mastocytosis include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. The Systemic Mastocytosis pipeline market research report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest...